| Document Date: 2013-12-12 17:28:07
Open Document File Size: 134,22 KBShare Result on Facebook
City Boston / Pfeffer / St. Louis / / Company NCH / / Event FDA Phase / / Facility Medical Center / MDA Clinic / Laboratory Examination GGT / University of Minnesota / Children’s Mercy Hospital / Kansas University / Nationwide Children’s Hospital / / IndustryTerm Treatment for hypertension / / MedicalCondition muscular dystrophy / congestive heart failure / hypertension / cardiomyopathy / left ventricular dysfunction / pulmonary anatomical variants / chronic / Duchenne muscular dystrophy / Skeletal deformities / syncope / myocardial infarction / Pulmonary / Criteria -Duchenne muscular dystrophy / heart failure / dilated cardiomyopathy / cardiac disease / left ventricle dysfunction / losartan Cardiomyopathy / dizziness / cough / myocarditis / light headedness / lightheadedness / / MedicalTreatment Treatment Protocol / Physical Therapy / / Organization University of Minnesota / / Person Allen / Brooke Upper Extremity / / Position statistician / cardiologist / care physician / evaluator / physical therapist / / Product Valsartan / IRB09-00066 / lisinopril / prednisone / captopril / losartan / hydrochlorothiazide / EF drops / DMD / / ProvinceOrState Kansas / Minnesota / Massachusetts / / Technology bioinformatics / Treatment Protocol / /
SocialTag |
MDA DMD Clinical Research Network NCH IRB09[removed]Compare efficacy of the angiotensin converting enzyme inhibitor (ACEi) lisinopril with angiotensin II receptor antagonist (ARB) losartan for the cardiomyopathy of DMD